CLINICAL TRIALS PROFILE FOR SITRAVATINIB
✉ Email this page to a colleague
Clinical Trials for Sitravatinib
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT02219711 ↗ | Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer | Active, not recruiting | Mirati Therapeutics Inc. | Phase 1 | MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK and Eph families. In this study, MGCD516 is orally administered to patients with advanced solid tumor malignancies to evaluate its safety, pharmacokinetic, metabolism, pharmacodynamic and clinical activity profiles. During the Phase 1 segment, the dose and regimen of MGCD516 will be assessed; during the Phase 1b segment, the clinical activity of MGCD516 will be evaluated in selected patient populations. Patients anticipated to be enrolled in Phase 1b will be selected based upon having a tumor type, including but not limited to, non small cell lung cancer and head and neck cancer positive for specific activating MET, NTRK2, NTRK3, or DDR2 mutations, MET or KIT/PDGFRA/KDR gene amplification, selected gene rearrangements involving the MET, RET, AXL, NTRK1, or NTRK3 gene loci, or having loss of function mutations in the CBL gene. In addition patients with clear cell renal cell carcinoma refractory to angiogenesis inhibitors or metastatic prostate cancer with bone metastasis will be enrolled. |
| NCT02664935 ↗ | National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | Active, not recruiting | AstraZeneca | Phase 2 | The trial consists of a series of parallel multi-centre single arm phase II trial arms, each testing an experimental targeted drug in a population stratified by multiple pre-specified actionable target putative biomarkers. The primary objective is to evaluate whether there is a signal of activity in each drug-(putative)biomarker cohort separately. A Bayesian adaptive design is adopted to achieve this objective and statistical details are given in the Protocol. |
| NCT02664935 ↗ | National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | Active, not recruiting | Cancer Research UK | Phase 2 | The trial consists of a series of parallel multi-centre single arm phase II trial arms, each testing an experimental targeted drug in a population stratified by multiple pre-specified actionable target putative biomarkers. The primary objective is to evaluate whether there is a signal of activity in each drug-(putative)biomarker cohort separately. A Bayesian adaptive design is adopted to achieve this objective and statistical details are given in the Protocol. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Sitravatinib
Condition Name
Clinical Trial Locations for Sitravatinib
Trials by Country
Clinical Trial Progress for Sitravatinib
Clinical Trial Phase
Clinical Trial Sponsors for Sitravatinib
Sponsor Name
